The globalization of the pharma industry
It seems the world is shrinking, as populations boom and more citizens rise to the level of the middle class. For the pharmaceutical industry, this growth means there are more patients that can afford quality healthcare than ever before, driving drugmakers to look beyond just the U.S., Europe and Japan.
Each of these new global markets — from China to India to Brazil — has its own set of challenges as well as potential rewards. The Chinese government, for instance, is pulling down regulatory hurdles that have slowed the development of innovative drugs in the country for years. On the other side of the Himalayas, drug manufacturers in India are working hard to become global players, but remain dogged by lingering quality control issues.
In this latest Spotlight edition, BioPharma Dive is going on a world exploration to highlight the wonders that these younger markets offer and the hurdles that still lie ahead.
As healthcare becomes a global economy, pharma companies face a slew of challenges as they try to commercialize in multiple markets across the globe. Read More >>
Despite a major regulatory shift, China's ascendency as the next global hub of drug R&D may still be a ways off. Read More >>
A poor patient population, a tricky tax code and turmoil within the government have created obstacles for pharma companies entering the Brazilian market. Read More >>
Indian drug manufacturers are looking to be bigger players in the global market, but quality control continues to be a challenge. Read More >>
Nineteen cities have bid to become the regulatory agency's new home, now that Brexit has forced the European Medicines Agency to relocate from London. Read More >>
CFDA announced draft guidelines that would allow Phase I trials in China to encourage simultaneous development alongside global trials. Read More >>
Follow Lisa LaMotta on Twitter